2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. iGluR
  4. QNZ46

QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting GluN2C/D (IC50=3.9 μM), GluN1/GluN2C (IC50=7.1 μM), and GluN1/GluN2D (IC50=182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration.

For research use only. We do not sell to patients.

QNZ46 Chemical Structure

QNZ46 Chemical Structure

CAS No. : 1237744-13-6

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

QNZ46 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE QNZ46

View All iGluR Isoform Specific Products:

View All Isoforms
AMPA Receptor NMDA Receptor Kainate Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting GluN2C/D (IC50=3.9 μM), GluN1/GluN2C (IC50=7.1 μM), and GluN1/GluN2D (IC50=182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration[1][2][3].

IC50 & Target

NMDA Receptor

 

Cellular Effect
Cell Line Type Value Description References
Oocyte IC50
> 300 μM
Compound: 46
Antagonist activity at rat recombinant NR1-NR2B receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2B receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
[PMID: 20684595]
Oocyte IC50
> 300 μM
Compound: 46
Antagonist activity at rat recombinant GLuR1 expressed in Xenopus oocytes assessed as inhibition of glutamate-induced current by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant GLuR1 expressed in Xenopus oocytes assessed as inhibition of glutamate-induced current by two-electrode voltage-clamp electrophysiology
[PMID: 20684595]
Oocyte IC50
229 μM
Compound: 46
Antagonist activity at rat recombinant NR1-NR2A receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2A receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
[PMID: 20684595]
Oocyte IC50
3 μM
Compound: 46
Antagonist activity at rat recombinant NR1-NR2D receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2D receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
[PMID: 20684595]
Oocyte IC50
6 μM
Compound: 46
Antagonist activity at rat recombinant NR1-NR2C receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
Antagonist activity at rat recombinant NR1-NR2C receptor expressed in Xenopus oocytes at holding potential of -40mV by two-electrode voltage-clamp electrophysiology
[PMID: 20684595]
In Vitro

Cell viability assay: QNZ46 (1-20 μM; 48 h) significantly reduces neuronal cell viability, and the inhibition rate was positively correlated with the concentration[2].
Immunofluorescence assay: QNZ46 (50 μM; 2 h) reduces myelin swelling in the myelin injury model and protected structural integrity[2].
WB assay: QNZ46 (10 μM; 24 h) decreases MLKL phosphorylation and RIP1 expression, may cause suppression of necroptosis pathways[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

QNZ46 Related Antibodies

Cell Viability Assay[1]

Cell Line: HEK293 cells expressing GluN1/GluN2D receptors
Concentration: 1-20 μM
Incubation Time: 48 h
Result: Reduced cell viability by 23-88% (IC50=3.9 μM), consistent with noncompetitive NMDA receptor inhibition.

Immunofluorescence[2]

Cell Line: Primary oligodendrocytes
Concentration: 50 μM
Incubation Time: 24 h
Result: Reduced ischemic injury-induced myelin decompaction (G-ratio increase from 0.67 to 0.90 μm) and preserved FluoroMyelin Red staining intensity.

Western Blot Analysis[2]

Cell Line: Rat optic nerve (RON)
Concentration: 10 μM
Incubation Time: 24 h
Result: Decreased phosphorylated MLKL (30% reduction) and RIP1 expression (40% reduction), indicating suppression of necroptosis pathways[2].
In Vivo

Ischemic stroke model: QNZ46 (20 mg/kg; i.p.; single administration) significantly reduces brain lesion volume and improved neurological function in transient middle cerebral artery occlusion (tMCAO) mice[2].
EAE model: QNZ46 (2 mg/kg+1 mg/kg CP465022; i.p.; once a day for 28 days) significantly reduces clinical scores in experimental autoimmune encephalomyelitis (EAE) mice and protected small-diameter myelinated axons in the spinal cord[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (male, 25-30 g, 8-12 weeks) + transient middle cerebral artery occlusion (tMCAO)[2]
Dosage: 20 mg/kg (50% DMSO/β-cyclodextrin)
Administration: Single i.p. injection 120 min prior to ischemia
Result: Reduced infarct volume by 68%, preserved myelinated axons in the external capsule, and improved neurological performance.
Animal Model: Animal Model: . C57BL/6 mice (female, 20-22 g, 8-12 weeks) + experimental autoimmune encephalomyelitis (EAE)[3]
Dosage: 2 mg/kg QNZ46 + 1 mg/kg CP465022 (0.5% methyl cellulose)
Administration: Daily i.p. injections from day 0 to day 28 post-immunization
Result: Combined QNZ46/CP465022 treatment reduced clinical severity and preserved small-diameter myelinated axons in spinal cord.
Molecular Weight

443.41

Formula

C24H17N3O6
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)C1=CC=C(N2C(/C=C/C3=CC=CC([N+]([O-])=O)=C3)=NC4=C(C=C(OC)C=C4)C2=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 4 mg/mL (9.02 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2552 mL 11.2762 mL 22.5525 mL
5 mM 0.4510 mL 2.2552 mL 4.5105 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2552 mL 11.2762 mL 22.5525 mL 56.3812 mL
5 mM 0.4510 mL 2.2552 mL 4.5105 mL 11.2762 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

QNZ46 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

QNZ461237744-13-6QNZ 46QNZ-46iGluRIonotropic glutamate receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
QNZ46
Cat. No.:
HY-15703
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.